Vanguard Investments Australia
RPRX icon

Vanguard Investments Australia’s Royalty Pharma RPRX Stock Holding History

Vanguard Investments Australia’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$11.8M Buy
209,942
+7,862
+4% +$409K 0.03% 445
2026
Q1 		$9.69M Buy
+202,080
New +$8.85M 0.03% 462

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Investments Australia's RPRX Position: Q2 2026 in Review

Vanguard Investments Australia increased its Royalty Pharma (RPRX) stake by 3.9% in Q2 2026, buying an estimated $409K and bringing the position to 209,942 shares worth $11.8M. The position accounts for 0.03% of the portfolio, ranked #445.

Vanguard Investments Australia first reported a position in RPRX in Q1 2026 and has held it in 2 quarters since. 641 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • Vanguard Investments Australia held 209,942 shares of Royalty Pharma worth $11.8M as of Q2 2026.
  • Vanguard Investments Australia bought 7,862 Royalty Pharma shares in Q2 2026, an estimated $409K.
  • Royalty Pharma made up 0.03% of Vanguard Investments Australia's portfolio in Q2 2026, its #445 holding.
  • Vanguard Investments Australia first reported a position in Royalty Pharma in Q1 2026 and has held it in 2 quarters since.
  • 641 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Vanguard Investments Australia's 13F filing for Q2 2026, filed 13 Aug 2026.